Moreover, experimental evidence has revealed that the inhibition of SEL1L3 expression leads to a reduction in the proliferation of renal cancer cells and triggers apoptosis, suggesting that SEL1L3 could potentially serve as a viable therapeutic target for renal cancer. The gene discussed is SEL1L3; the disease is renal carcinoma.